E150: Israel/Gaza escalating or not? EU censorship regime, Penn donors revolt, GLP-1 hype cycle

The episode’s central geopolitical judgment was that Israel’s delayed Gaza ground invasion likely reflected military danger and diplomacy, not simple indecision. Sacks pointed to Hamas tunnels, IEDs, a possible Hezbollah front, hostage risk and private U.S.-Israeli talks as reasons Israel might pause.

Sacks argued Hamas’s October 7 attack may have been strategically aimed at wrecking Arab-Israeli normalization, especially a prospective Saudi deal. His larger conclusion was that bypassing the Palestinian question had failed: Saudi talks froze, older accords looked vulnerable, and Palestinian statehood returned to the center of regional diplomacy.

Jason Calacanis said five people of Palestinian descent he dined with in Dubai condemned Hamas yet felt Western debate ignored Palestinian living conditions. Their complaint was not support for Hamas but perceived Western unwillingness to hold Israel to human-rights standards, a distinction he said sharply reduced his optimism about the conflict.

The discussion argued that Netanyahu’s coalition had already narrowed room for a two-state compromise before October 7. Sacks highlighted Itamar Ben-Gvir’s Al-Aqsa provocations, coalition claims over Judea and Samaria, and expanding West Bank settlements as political constraints on renewed negotiations.

Donor leverage, not just campus protest, became a major second-order effect of the war. The episode cited Wexner ending Harvard ties, a Kennedy School board resignation and Penn donor anger, alongside FIRE’s ranking of Harvard last and Penn second-last for campus free speech.

The hosts’ strongest tech-policy concern was that Europe’s Digital Services Act could export EU moderation rules beyond Europe. They focused on obligations for large platforms, researcher access, crisis cooperation and fines up to 6% of global revenue, arguing companies may find global compliance cheaper than maintaining separate systems.

Friedberg’s most useful GLP-1 warning was muscle loss, not weight loss itself. He cited studies in which as much as 40% of lost weight came from lean mass and said stopping the drug without behavior change can produce rapid regain; Jason said lifting, walking and high protein limited his own muscle loss.

The GLP-1 boom had already become a major market trade, not merely a medical story. Chamath said Morgan Stanley’s basket of GLP-1 winners versus threatened healthcare companies produced an extraordinary spread, while one positive Novo Nordisk trial triggered a reported $3.6 billion sell-off in dialysis stocks.